A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Oral Tomivosertib (eFT-508) in Subjects With Hematological Malignancies

Exclusion Criteria

• •1. Central nervous system malignancy
• •2. Gastrointestinal disease
• •3. Significant cardiovascular disease
• •4. Significant ECG abnormalities.
• •5. Ongoing risk for bleeding due to active peptic ulcer disease, bleeding diathesis or requirement for systemic anticoagulation
• •6. Ongoing systemic bacterial, fungal, or viral infection (including upper respiratory tract infections)
• •7. Pregnancy or breastfeeding.
• •8. Major surgery within 4 weeks before the start of study therapy.
• •9. Ongoing immunosuppressive therapy, including systemic or enteric corticosteroids
• •10. Use of drugs that could prolong the QT interval within 7 days before the start of study therapy.
• •11. Use of drugs that might pose a risk of a drug-drug interaction within 2-7 days before the start of study therapy.